The design requirements for current heavy-particle accelerators operated within a hospital to deliver radiation therapy must satisfy both clinical and research needs.
INTRODUCTION
More than forty years have passed since protons were first used in treating localized tumors in humans. In the meantime, twenty facilities worldwide have treated more than 23,000 patients with proton beams. ' Until 1990 , all of these facilities used previously existing accelerators, which were designed for physics research and later modified for medical use. From 1987 to 1990, the first medical proton accelerator was designed and built for the Loma Linda University Proton Accelerator Facility' (LLUPAF) in Loma Linda, CA. This project was a cooperative effort between Loma Linda University, Fermi National Accelerator Laboratory (Fermilab), and Science Applications International Corporation (SAIC). Since 1990, over four thousand patients have been treated with protons at LLUPAF. To date, four more hospital-based facilities are under construction: one in Boston, MA and three in Japan. In addition, many new facilities are in the planning stages in the US, Europe, and Japan.
The advantages of a hospital-based facility over a laboratory-based facility are great. In a hospital, health care professionals can work as a team more efficiently and more effectively in planning, preparing and executing high precision radiotherapy treatments for each patient. In addition, the expensive ancillary equipment (such as CT) and hospital staff are already in place for patient preparation and treatment. Beam time can be dedicated for medical use, which is not the case at physics research laboratories. Finally, anesthetized and other nonambulatory patients can be treated only in a hospital setting. In many of the new facilities, basic research in radiation biology will also need to be included in the facility requirements as well. In this paper, we examine the primary requirements that any new proton or light ion accelerator will face in a hospital or clinical setting.
PROTON DOSIMETRY
The primary advantage of protons over therapeutic x-rays is shown in dose vs. penetration data (Fig.1) . One sees that protons give a higher dose at deeper sites and a lower dose near the entrance to the body, where healthy tissue is likely to be. Unlike x-rays, protons have no "exit dose," which spares healthy tissue beyond the Bragg peak. depth tor therapeutic proton, x-ray, and electron beams. The monoenergetic Bragg peak is the narrow one on the right. Tfie spread-out Bragg peak (SOBP) is generated from mono-energetic peaks as shown in Fig. 2 . The maximum depth of beam penetration and width of the SOBP can be controlled by the beam energy.
The energy of the proton beam can be so adjusted from the accelerator that protons penetrate to the correct depth for each tumor. By adding Bragg peaks of successively lower 0-7803-5573-3/99/$1 O.OO@ 1999 IEEE.
energies and intensities ( Fig. 2 ) a SOBP can be generated which has uniform dose over the entire depth of the tumor. The energy accuracy for each Bragg peak is quite precise and dictates the energy accuracy requirement for the accelerator, as is discussed later. The ability to achieve dose uniformity in depth as well as transverse to the beam direction within the tumor volume is a primary requirement in all radiotherapy treatments. 12 14 Depth (an) Fig.2 : A spread-out Bragg peak (SOBP) generated from the addition of mono-energetic Bragg peaks. The dose uniformity in the SOBPbetween 4 cm and 12 cm is less than +/-2% with no energy or intensity errors.
ACCELERATOR 'SYSTEM REQUIREMENTS
The primary function of any proton therapy accelerator is to provide treatment rooms with-a specified energy and Examples of active and passive beam delivery systems are shown in Fig. 3a and 3b. For active beam scanning, the accelerator control system must contain a library of energy ramp sets that can be executed in rapid succession to generate SOBPs (Fig.2) at the patient. The exact sequence of energies and intensities must be transmitted electronically from the treatment planning computer for each patient. Fig . 4a and 4b show the ranges of energy and intensity that are required for proton therapy. The energy range most often specified for a therapy accelerator is 70 to 250 MeV, which corresponds to 3 to 40 cm range in water or soft tissue. Fig. 4b shows the fluence requirements in units of protons/cm2/Gy and should be scaled using the appropriate field size, dose rate, and modulation depth that is desired. The ideal facility should have efficient beam extraction and beam delivery systems which will require the minimum beam current (protons/min) to achieve treatment times below several minutes with doses of approximately 2 Gray. This minimizes the risk of an inadvertent overdose to the patient. 
GENERAL REQUIREMENTS
Some obvious requirements only need mentioning for completeness, but require careful attention for a successful facility. Accelerator reliability is one of the top priorities for all therapy operations. For example, the LLUPAF synchrotron has enjoyed 98% uptime for patient treatments with five treatment days per week and 24-hour operations.
The proton synchrotron services four treatment rooms and one research room. The high reliability has been accomplished with the help of a maintenance team that monitors various systems to perform preventive maintenance before failures occur, particularly with magnet power supplies, vacuum components and water cooling systems. Accelerator reliability is extremely important, particularly for patients in the middle of threeor four-week treatment schedules. Clinical data have shown that patients whose treatments have been interrupted for two or more weeks have increased risk of tumor recurrence compared to patients who keep regularly scheduled treatments. Most of the accelerator down time (2%) over the past three years was due to power outages that caused vacuum failures and magnet power supply problems related to chilled water systems. Oftentimes, any missed treatments can be made up on weekends or 'by increasing daily dose fractions.
A new facility must be designed for high patient throughput to be financially solvent and to rapidly acquire statistically significant clinical data for each disease site being treated. High patient throughput requires a large number of activities to run smoothly. On the accelerator end, the ability to switch beam energies and treatment room destinations quickly and reliably is crucial to reducing patient waiting times. For the same reason, the dose rate (or intensity) from the accelerator must also be sufficiently high to avoid limiting patient throughput. At LLUPAF, the average treatment time per patient is about two minutes Bnd the time to switch treatment rooms less than one minute. Since the time to align the patient requires typically ten to fifteen minutes, the Proceedings of the 1999 Particle Accelerator Conference, New York, 1999 13 accelerator performance does not currently limit the patient throughput. The Loma Linda facility has demonstrated patient throughput as high as 125 patients in-a 16-hour b y .
Attention should also be given to power supply stability in accelerator systems. This affects energy, intensity, and position stability of extracted beams. In beam transport lines, dipole bending magnet stability effects position stability of the beam in the treatment rooms. Typical values of beam position tolerance require fluctuations less than f lmm in the treatment rooms, at the end of a beam line that may be 50 meters from the accelerator. In some cases, the current output from a bending magnet power supply in the beam lines may require current stability to the magnets better than 0.1%. Reproducible and stable current output to all beam transport magnets is crucial to avoid beam losses during treatment and to maintain correct beam position in the treatment rooms.
Efficiency of beam extraction from the accelerator is an area where higher efficiency will lower the radiation activation of accelerator components and make serviceability much easier. Shielding requirements for personnel will also be lower. Higher beam transport efficiency through the switchyard will lower the required intensity from the accelerator, thereby reducing neutron exposure to personnel and the general public. Typical values for beam extraction efficiency and beam transport efficiency at LLUPAF are 90%, with extracted beam currents less than 5 nA (time averaged). This leads to very low equipment activation and low exposure to personnel.
REQUIREMENTS FOR BIOLOGICAL STUDIES
A large NASA program has begun at Loma Linda to investigate the health effects of space radiation on astronauts on long missions. These experiments present requirements that differ from therapy beam requirements. In general, they require very low dose exposures, extending from one day to several weeks. To accommodate these requirements, the accelerator must have intensity control that is roughly 100 times lower than therapy beams with energies from 20 to 300 MeV. Small energy changes (< 4 MeV) of once per second would be required to cover this large dynamic range. Many of these irradiations must be done between patient treatments and therefore require a separate room with semipermanent biologic setups. Accelerator and beam line controls must be able to switch between a treatment room and the research room fast enough (less than one minute) so that patient wait times are low. In addition, measurements of mammalian cell damage on the sharp distal edge falloff of the Bragg peak (see Fig. 1 
INTENSITY REQUIREMENTS FOR BEAM SCANNING
The stacked Bragg peaks in Fig. 2 show that the integrated dose for each peak is different. A dynamic range of 20: 1 is required to obtain the desired dose uniformity throughout the SOBP. Approximately ten to twenty energies will be required for each treatment to generate the desired dose uniformity over the entire depth of the tumor. Studies have showns that it is much more time efficient to vary the accelerator intensity for different proton energies than to vary the dwell time for individual energies to achieve the 20:l range of doses between Bragg peaks. Variable intensity control is, therefore, desirable. The ability to control the beam current from the accelerator with an accuracy of f 10% over the 20:l dynamic range also is desirable. For beam scanning applications, it is desirable to have the intensity as uniform as possible as the beam is swept across a target volume, to. "paint" a uniform dose distribution. The detailed requirement depends on the beam spot size, 0. in the patient and the sweep speed, v, of the scanning magnets. In general, all frequencies below f = v h should have intensity ripple below f 3% to have dose errors less than +-3% in the plane transverse to the beam direction. For example, a typical beam diameter of 1 cm and magnet sweep speed of 1 cm/ms, yields an intensity stability requirement of f 3% for frequencies below 1 kHz.
ENERGYCONTROL REQUIREMENTS FOR BEAM SCANNING
Due to the sharp falloff at the distal edge of a monoenergetic Bragg peak, each energy must be delivered very precisely relative to the preceding one to generate a superposition of Bragg peaks (or SOBP) with good dose uniformity throughout the depth of the target. When the mono-energetic beams are generated from the accelerator and not from passive devices in the treatment room beam delivery system, much tighter energy control is required A minimum targeted dose uniformity throughout the tumor volume is currently k 3%. Note that the distal dose falloff is sharper at lower energies due to lower energy straggling for particles of less range in tissue. Therefore, the dose uniformity, in depth, is more sensitive to range errors at low energies than at high energies. The effects of a 0.7 MeV error (or equivalently 1 mm of range) from one of the Bragg peaks can be clearly seen in Fig. 5 , where the dose non-uniformity has increased to 10% near the distal edge. Further simulations have shown that an energy accuracy of f 0.1 MeV to f 0.3 MeV (see Table  I , below) is necessary to insure f 3% dose uniformity in the SOBP. Comparison of the three basic accelerator types for proton therapy is outlined in Table 2 is taken from the Hitachi accelerator, which uses multiturn injection. The cost for each type of accelerator has not been included because it depends on the vendor's amortization schedule and the quantity of units to be sold. For example, the cost of development, engineering and overhead may be included differently among vendors. This dependence is probably larger than the difference between economical and more expensive designs. Roughly speaking, cost ranges can be expected to fall between eight and fifteen million dollars (in 1999 dollars) for the three accelerator types, with maximum energy capabilities between 220 to 270 MeV. * While the energy extracted from the cyclotron is fixed, a variable thickness plastic wheel, which intercepts the beam, can reduce the energy to the desired level in a continuous fashion. The main penalties are higher emittance from multiple scattering and higher intensity losses from the energy degrading process which contribute to higher shielding requirements.
These intensities can exceed 100 pA but they can be hardware limited at the ion source to the 30 to 300 nA range. *** Beam intensity uniformity for active beam scanning generally requires intensity regulating feedback loops to achieve uniform intensity. First demonstrated use of a scanning beam system occurred at the Berkeley synchrotron6 in 1992. Adequate spill uniformity was achieved using intensity control feedback loops. ** AHAN -As High As Necessary.
SUMMARY
The design effort for developing a hospital-based heavycharged-particle facility mandates a highly orchestrated program that requires the hospital personnel teams to work closely with the architects, physicists, and engineers of the vendors involved in the facility. The clinical beam delivery systems and the integrated control systems needed for the facility are complex and are, in general, less well developed than the accelerators, making an orchestrated development effort all the more necessary to ensure that all systems, including the accelerator,, function for the benefit of the patient.
